Account
Watchlists
Bookmarks
Pricing
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Curis Lifesciences Limited is a pharmaceutical manufacturer specializing in a diverse range of products including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. Originating as a partnership firm in 2010, the company has evolved to operate through multiple business verticals: loan license manufacturing, contract manufacturing for domestic suppliers and merchant exporters, and direct exports of its own brands. Curis Lifesciences primarily serves domestic markets but also has a presence in international territories like the Republic of Yemen and Kenya through direct exports, and numerous other countries via merchant exporters. The company's manufacturing facility in Gujarat is WHO-GMP certified and holds approvals for several international health authorities.
Nov 07, 2025
Nov 11, 2025
Nov 14, 2025
SME
Closed
27.52 Cr
27.52 Cr
0 Cr
₹120 - ₹128
1000
Our Company intends to utilize the Net Proceeds from the Issue for the following objects:
Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities to enhance automation in testing and packaging processes, aiming to increase productivity and efficiency.
Capital Expenditure towards Construction of a new Storage Facility to support expanded manufacturing operations and inventory management.
Pre-payment or Repayment of a portion of outstanding Secured Loans to reduce debt servicing costs and strengthen the balance sheet.
Funding the expenses related to Product Registrations in various other countries to expand the company's direct export and own-brand manufacturing business vertical.
To meet the growing Working Capital Requirements of the business, driven by an increase in the scale of operations.
To fund General Corporate Purposes, which may include strategic initiatives, brand-building exercises, and meeting unforeseen business exigencies.
—
—
55.25%
27.83%
37.62%
—
12.43%
19.41%
12.64
Diverse product portfolio including tablets, capsules, oral liquids, and ointments.
Flexible business model with multiple revenue streams: loan license, contract manufacturing, and direct exports.
Manufacturing facility is WHO-GMP certified with approvals from regulatory bodies in Kenya, Yemen, Philippines, and Nigeria.
Established relationships with a broad clientele of domestic and international pharma marketers.
High concentration of manufacturing operations at a single facility in Sanand, Gujarat, posing operational risks.
Significant revenue dependence on a limited number of key customers.
History of delays in the repayment of loan installments, which could impact creditworthiness.
Operations are conducted from a leased registered office, which does not provide long-term asset security.
Leverage IPO proceeds to upgrade manufacturing facilities and build a new storage facility, enhancing production capacity and efficiency.
Expand direct export business by obtaining product registrations in new international markets.
Capitalize on the growing Indian pharmaceutical market, which is projected to reach approximately $130 billion by 2030.
Benefit from government initiatives like the Production Linked Incentive (PLI) scheme to boost domestic manufacturing.
Subject to a highly regulated industry with stringent quality standards and the need for continuous renewal of licenses and approvals.
Vulnerability to fluctuations in raw material prices due to the absence of long-term supply agreements.
Intense competition from both large multinational corporations and smaller unorganized local players.
Exposure to global economic uncertainties and foreign currency exchange rate fluctuations that could impact export revenues and profitability.